Please ensure Javascript is enabled for purposes of website accessibility

Why Gilead Sciences Stock Is Jumping Today

By Keith Speights - Jan 19, 2021 at 11:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A Wall Street analyst upgraded the biotech stock.

What happened

Shares of Gilead Sciences (GILD 0.40%) were jumping 6.7% higher as of 11:21 a.m. EST on Tuesday. The gain came after Morgan Stanley analyst Matthew Harrison upgraded the stock to overweight from equal weight. Harrison set a one-year price target for Gilead of $83, reflecting a premium of 31% above the closing price on Friday. In addition, the U.S. Supreme Court declined to review Merck's (MRK -0.47%) appeal of a lower federal court's decision to overturn a $2.54 billion verdict against Gilead for infringing patients with its hepatitis C drugs Harvoni and Sovaldi. 

So what

The bigger catalyst for Gilead today was definitely Morgan Stanley's upgrade. It wasn't all that surprising that the Supreme Court opted not to take on Merck's case. But it was at least a little surprising that Matthew Harrison expects the biotech stock to soar to $83.

Man wearing a coat and tie with a thumbs up

Image source: Getty Images.

Harrison is certainly more bullish than most Wall Street investors. The average price target for Gilead is a little over $72, which still reflects a double-digit upside compared to the stock's closing price at the end of last week. 

Gilead could meet Harrison's optimistic outlook. However, it won't be easy. COVID-19 therapy Veklury ranked as the company's primary revenue growth driver in the third quarter. Sales growth will likely be harder to come by later this year as more people across the world receive COVID-19 vaccines.

Now what

In just a few weeks, Gilead will announce its fourth-quarter results. Veklury will likely again be the big story. Going forward, though, the biotech's big investments in oncology will need to pay off for Gilead to return to its winning ways of several years ago.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$65.27 (0.40%) $0.26
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$93.31 (-0.47%) $0.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.